^
    Back
    Association details:
    Biomarker:PD-1 expression
    Cancer:Cutaneous Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Surg
    Title:

    Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma

    Published date:
    07/21/2022
    Excerpt:
    The purpose of this study was to construct a ferroptosis-related lncRNA signature to predict prognosis and immunotherapy efficacy in CM….Low-risk patients whose disease expressed PD1 or CTLA4 were likely to respond better to ICIs.
    DOI:
    10.3389/fsurg.2022.860806